Trial Profile
A Phase III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of HBI Pentavalent (DTwP-Hb-Hib[Liquid]) Combination Vaccine with Pentavac SD® Vaccine when Administered in Three Doses to 6-8 weeks old Healthy Infants - Pentavalent Phase III Clinical trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Hib-DTP-hepatitis B vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors Indian Immunologicals
- 19 Jul 2019 Primary endpoint has been met. (Proportion of subjects achieving seroconversion and seroprotection against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type B four to six weeks after three doses of primary immunization with HBI Pentavalent (DTwP-Hb-Hib[Liquid]))
- 19 Jul 2019 Results published in the Vaccine
- 06 Feb 2017 Status changed from recruiting to completed.